The Efficacy And Safety Of Tacrolimus On The Myasthenia Gravis Patients Who Are Not Sufficient With Glucocorticoid

Objectives:To assess the efficacy and safety tacrolimus on the Myasthenia Gravis patients who are not sufficient with glucocorticoid.Method:16patients with myasthenia gravis were followed up in a double-blind, randomized, placebo controlled study.The16cases were randomly divided into control group (placebo group) and tacrolimus group and all the patients were treated for24weeks. QMG scale was get as major index to evaluate therapeutic affection on the12th week and the24th week and the MMT score and ADL score were the secondary therapeutic affection. EKG,liver function,urine and blood routine test were to evaluate medical safety.Results:1,16patients include7patients were in control group excluding1patient;9patients in tacrolimus group excluding0patient.2, There was no significant difference in patients’characteristics, history and initial symptoms, QMG score, MMT score and ADL score.3, The QMG score, MMT score and ADL score with tacrolimus on the12th week and the24th week after treatment had statistically greatly improved than those before curing (p<0.05).But the control group was not different form the beginning. The QMG score, MMT score and ADL score with tacrolimus on the24th week were greatly improved than on the12th week(p<0.05).4, Their EKG,liver function,urine and blood routine test were all in normol state before curing. There were2patients,1in control group and1in tacrolimus group,showing adverse events and creatinine were uncommon on the12th week and the indexes were common after2weeks.Conclusion:The tacrolimus on the myasthenia gravis patients who are not sufficient with glucocorticoid was effective and safe.